APPLY TREATMENT TO CLINICAL SYNDROMES

Viral Hepatitis Pharmacotherapy

Viral hepatitis includes infections with different transmission patterns, natural histories, and treatment goals. Identifying the virus and determining whether infection is acute, chronic, or resolved are necessary before selecting therapy.

The treatment goal may be supportive recovery, durable suppression, prevention of progression, or virologic cure (Chan, 2026).

Distinguish Hepatitis A–E

Hepatitis A is usually transmitted through the fecal-oral route and does not become chronic. Treatment is primarily supportive; vaccination and selected post-exposure interventions provide prevention.

Hepatitis B is transmitted through blood, sexual exposure, and perinatal exposure. Chronic infection can lead to cirrhosis and hepatocellular carcinoma. Vaccination prevents infection, while antiviral therapy generally suppresses established chronic disease.

Hepatitis C is primarily bloodborne and frequently becomes chronic. Direct-acting antiviral therapy can achieve cure. There is no routinely available preventive HCV vaccine.

Hepatitis D requires hepatitis B infection. HBV vaccination prevents HDV infection in susceptible people by preventing the necessary HBV infection.

Hepatitis E is commonly enterically transmitted. Chronic infection can occur in immunocompromised patients, and pregnancy can increase the consequences of infection in particular epidemiologic settings (Chan, 2026).

Interpret Hepatitis B Serology

Hepatitis B surface antigen indicates current infection. Persistence for at least six months supports chronic infection.

Antibody to surface antigen indicates immunity. Antibody to core antigen indicates exposure to actual infection and is not produced by vaccination alone.

Common patterns include:

Surface antigen negative, core antibody negative, surface antibody positive: immunity consistent with vaccination
Surface antigen negative, core antibody positive, surface antibody positive: resolved infection
Surface antigen positive: current infection requiring further assessment

An isolated core antibody result has several possible explanations and requires contextual interpretation. HBV DNA measures replication; alanine aminotransferase reflects liver injury but does not independently define disease activity or treatment eligibility (Chan, 2026).

Select Hepatitis B Treatment

Assess HBV DNA, aminotransferases, fibrosis or cirrhosis, hepatitis B e antigen status, comorbidities, and relevant host factors. Cirrhosis and viral replication substantially affect the treatment decision.

Common high-barrier oral options include entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide. Representative adult doses include entecavir 0.5 mg daily on an empty stomach in an appropriate nucleoside-naive patient, tenofovir disoproxil fumarate 300 mg daily, or tenofovir alafenamide 25 mg daily with food. Prior resistance, renal function, hepatic status, and other factors can change eligibility or dosing.

Entecavir should not be used as monotherapy in a person with untreated or inadequately treated HIV because HIV resistance can emerge. Treatment commonly continues long term. Suppression of HBV DNA does not usually represent eradication. Avoid unsupervised discontinuation because clinically important flares can occur (Chan, 2026). Before B-cell-depleting therapy, transplantation, cytotoxic chemotherapy, or other high-risk immunosuppression, screen with hepatitis B surface antigen, surface antibody, and core antibody; antiviral prophylaxis or structured HBV DNA and laboratory monitoring may be required.

Diagnose and Stage Hepatitis C

A reactive HCV antibody test indicates exposure. HCV RNA establishes current infection. Antibody may remain positive after spontaneous clearance or successful treatment, so repeat antibody testing does not establish cure or reinfection.

Before treatment, assess fibrosis, medication interactions, kidney and liver function, HBV and HIV status, and pregnancy. Patients with cirrhosis, previous treatment, transplantation, or other complicating features may require a different pathway (Chan, 2026).

Use a Defined HCV Treatment Pathway

For eligible treatment-naive adults without cirrhosis, the AASLD/IDSA simplified pathway includes:

Glecaprevir/pibrentasvir 300/120 mg orally daily with food for eight weeks
Sofosbuvir/velpatasvir 400/100 mg orally daily for twelve weeks

Eligibility must be established before using these regimens. NS3/4A protease inhibitor-containing regimens, including glecaprevir, should not be used in decompensated cirrhosis. Medication reconciliation and interaction screening are required. Patients with current pregnancy, positive hepatitis B surface antigen, prior treatment, or other listed exclusions need an alternative evaluation pathway.

Assess HCV RNA at least twelve weeks after treatment completion to establish sustained virologic response. Patients taking glucose-lowering medications or warfarin may require additional monitoring during treatment (American Association for the Study of Liver Diseases & Infectious Diseases Society of America [AASLD/IDSA], n.d.).

Monitor Beyond the Prescription

For HBV, follow viral suppression, aminotransferases, renal safety when relevant, adherence, and disease progression. Monitoring intervals depend on treatment phase and disease status.

For HCV, cure does not provide immunity against reinfection. Patients with ongoing exposure require risk reduction and appropriate RNA-based testing. Patients with cirrhosis remain in liver surveillance pathways after cure.

Explain alcohol-related liver risk, medication safety, vaccination needs, and prevention of bloodborne transmission. New jaundice, confusion, bleeding, or other evidence of hepatic decompensation requires prompt assessment (Chan, 2026).

Related YourDNP Resources

Content last reviewed:

September 15, 2026

References

American Association for the Study of Liver Diseases, & Infectious Diseases Society of America. (n.d.). Simplified HCV treatment for treatment-naive adults without cirrhosis. HCV Guidance. Retrieved September 15, 2026, from https://www.hcvguidelines.org/guidance/simplified-hcv-treatment-for-treatment-naive-adults-without-cirrhosis/

Chan, J. (2026). Viral hepatitis. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.